Loading...
Please wait, while we are loading the content...
Similar Documents
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
| Content Provider | Scilit |
|---|---|
| Author | Kantarjian, Hagop M. Giles, Francis J. Bhalla, Kapil N. Pinilla-Ibarz, Javier Larson, Richard Gattermann, Norbert Ottmann, Oliver Hochhaus, Andreas Radich, Jerald P. Saglio, Giuseppe Hughes, Timothy Martinelli, Giovanni Kim, Dong-Wook Shou, Yaping Gallagher, Neil J. Blakesley, Rick Baccarani, Michele Cortes, Jorge Coutre, Philipp D. Le |
| Copyright Year | 2011 |
| Description | Nilotinib is a potent selective inhibitor of the BCR-ABL tyrosine kinase approved for use in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), and in CML-CP and CML-accelerated phase after imatinib failure. Nilotinib (400 mg twice daily) was approved on the basis of the initial results of this phase 2 open-label study. The primary study endpoint was the proportion of patients achieving major cytogenetic response (CyR). All patients were followed for ≥ 24 months or discontinued early. Of 321 patients, 124 (39%) continue on nilotinib treatment. Overall, 59% of patients achieved major CyR; this was complete CyR (CCyR) in 44%. Of patients achieving CCyR, 56% achieved major molecular response. CyRs were durable, with 84% of patients who achieved CCyR maintaining response at 24 months. The overall survival at 24 months was 87%. Adverse events were mostly mild to moderate, generally transient, and easily managed. This study indicates that nilotinib is effective, with a manageable safety profile, and can provide favorable long-term benefits for patients with CML-CP after imatinib failure. This trial was registered at www.clinicaltrials.gov as #NCT00109707. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916554/pdf |
| Ending Page | 1145 |
| Page Count | 5 |
| Starting Page | 1141 |
| DOI | 10.1182/blood-2010-03-277152 |
| Journal | Blood |
| Issue Number | 4 |
| Volume Number | 117 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2011-01-27 |
| Access Restriction | Open |
| Subject Keyword | Hematology Safety Treatment Survival Chronic Myeloid Leukemia Cml Nilotinib Ccyr Journal: Blood (Vol- 79, Issue- 4) |
| Content Type | Text |
| Resource Type | Article |
